SCHEMBL4248277

SCHEMBL4248277

O=C1OCCc2cc(-c3ccccc3)nc(N3CCCC3)c21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 9/20 0.45
HPGD P15428 4/20 0.43
KDM4E B2RXH2 5/20 0.43
TSHR P16473 5/20 0.43
ALDH1A1 P00352 4/20 0.43
CASP1 P29466 2/20 0.43
CASP7 P55210 2/20 0.43
GAA P10253 1/20 0.43
KMT2A Q03164 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
LMNA P02545 2/20 0.41
HTT P42858 2/20 0.41
USP2 O75604 1/20 0.41
MAPK1 P28482 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
TDP1 Q9NUW8 1/20 0.39
POLB P06746 1/20 0.39
GPR55 Q9Y2T6 1/20 0.39
MAPT P10636 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4067394 0.99 HSD17B10 (0.47) HSD17B10HPGDKDM4ETSHRALDH1A1
SCHEMBL4064270 0.91 HSD17B10 (0.51) HSD17B10HPGDKDM4ETSHRALDH1A1
SCHEMBL4063851 0.78 ALDH1A1 (0.62) HSD17B10HPGDKDM4ETSHRALDH1A1
SCHEMBL4066864 0.78 ALDH1A1 (0.39) HSD17B10HPGDKDM4EALDH1A1KMT2A
SCHEMBL4063554 0.78 PDE4B (0.43) HSD17B10HPGDKDM4EALDH1A1KMT2A
SCHEMBL4067545 0.78 PDE4B (0.37) HSD17B10HPGDKDM4ETSHRALDH1A1
SCHEMBL4067298 0.78 ALDH1A1 (0.41) HSD17B10HPGDKDM4ETSHRALDH1A1
SCHEMBL4248613 0.77 KDM4E (0.43) HSD17B10HPGDKDM4EALDH1A1GAA
Hydrochloric Acid SCHEMBL4247459 0.76 PDE4B (0.36) HSD17B10HPGDKDM4ETSHRALDH1A1
SCHEMBL4749923 0.76 KDM4E (0.44) HSD17B10HPGDKDM4ETSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7601736-B2 Such as 3,4-dihydro-pyrano[3,4-c]pyridine-1-on; cytokine suppressive antiinflammatory drugs; analgesics SK CHEMICALS CO., LTD. (KR) 2009-10-13 US claimed
EP-1706412-A4 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK CHEMICALS CO LTD (KR) 2009-03-18 EP claimed
US-20070254909-A1 Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same SK CHEMICALS CO., LTD. (KR) 2007-11-01 US claimed
JP-2007517024-A 2007-06-28 JP claimed
EP-1706412-A1 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK Chemicals, Co., Ltd. (KR) 2006-10-04 EP claimed
WO-2005063768-A1 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK CHEMICALS, CO., LTD. (KR) 2005-07-14 WO claimed
US-7601736-B2 Such as 3,4-dihydro-pyrano[3,4-c]pyridine-1-on; cytokine suppressive antiinflammatory drugs; analgesics SK CHEMICALS CO., LTD. (KR) 2009-10-13 US disclosed
EP-1706412-A4 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK CHEMICALS CO LTD (KR) 2009-03-18 EP disclosed
US-20070254909-A1 Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same SK CHEMICALS CO., LTD. (KR) 2007-11-01 US disclosed
EP-1706412-A1 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK Chemicals, Co., Ltd. (KR) 2006-10-04 EP disclosed
WO-2005063768-A1 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK CHEMICALS, CO., LTD. (KR) 2005-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254909-A1 Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same IL5, IL1B, P2RY4 HSD17B10 3499/4885HPGD 72/4885KDM4E 405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.